Perimenopause is not a failed menopause test.
It is the transition before menopause. Menopause is the point reached after 12 months without a period, when pregnancy, hormonal contraception, surgery, or another medical cause does not explain the bleeding pattern.
The STRAW+10 framework describes reproductive aging as stages around the final menstrual period. The final menstrual period is known only in hindsight, which is why a single lab result often creates more confusion than clarity after 45. [1]
The practical difference
| Question | Perimenopause | Menopause |
|---|---|---|
| What is it? | The transition leading up to the final menstrual period | The point reached after 12 months without a period |
| Can periods still happen? | Yes. They may be irregular, skipped, closer together, or farther apart | No period for 12 months, unless a medication or condition obscures the pattern |
| Can symptoms start? | Yes. Hot flashes, night sweats, sleep disruption, mood changes, and vaginal symptoms can start before periods stop | Yes. Some symptoms continue or appear after the final period |
| Is one follicle-stimulating hormone test enough after 45? | Usually no | Usually no |
| What changes the decision? | Bleeding pattern, age, symptoms, contraception, medications, and red flags | Postmenopausal bleeding, ongoing symptoms, bone/genitourinary/metabolic risks |
American College of Obstetricians and Gynecologists guidance gives the practical clinical boundary: hormone testing usually is not needed when age, symptoms, and period changes fit perimenopause. Menopause is generally identified after 12 months without a period when another cause is not explaining the bleeding pattern. [2]
How the stage changes the next decision
The label is useful only if it changes the next question.
| Pattern | Most likely frame | Better next question |
|---|---|---|
| Age 45 or older, periods still happening but timing is changing, with new hot flashes or night sweats | Perimenopause | Are symptoms bothersome enough to treat, and is bleeding still within an expected pattern? |
| No period for 12 months, not explained by pregnancy, surgery, or hormones | Menopause | Are symptoms persisting, and do bone, genitourinary, cardiometabolic, or treatment-timing risks need review? |
| On combined hormonal contraception, high-dose progestogen, or an intrauterine device that changes bleeding | Stage may be obscured | Do not rely on bleeding pattern or one follicle-stimulating hormone result alone; review age, symptoms, contraception, and pregnancy prevention. |
| Symptoms and cycle change between ages 40 and 45 | Possible early menopause or perimenopause | Consider whether serum follicle-stimulating hormone is useful and whether early-menopause support is needed. [2] |
| Symptoms or absent/irregular periods before 40 | Possible primary ovarian insufficiency | Evaluate rather than assuming ordinary perimenopause. Premature ovarian insufficiency changes bone, fertility, cardiovascular, and hormone-replacement discussions. [4] |
| Bleeding after 12 months without a period | Postmenopausal bleeding | Evaluate the bleeding before treating it as routine transition change. [3] |
This is why the best first assessment is not "What is my hormone number?" It is age, period pattern, contraception, pregnancy possibility, symptoms, medications, uterine history, and red flags.
Why one hormone test can mislead after 45
After the mid-40s, American College of Obstetricians and Gynecologists guidance says hormone testing usually is not needed when age, symptoms, and period changes fit perimenopause. [2]
That does not mean symptoms are vague or imaginary.
It means the transition moves. A blood draw is a snapshot. A bleeding-and-symptom pattern is the movie.
Testing has a different role before 45, and an even more important role before 40 because primary ovarian insufficiency changes bone, fertility, cardiovascular, and treatment decisions. [2] [4]
There is also a contraception trap. A person can be in perimenopause and still ovulate sometimes. A symptom-treatment plan does not automatically provide contraception, and hormonal contraception can hide the bleeding pattern that would otherwise help with staging.
What to do next at each stage
"Perimenopause" is often the better fit when periods are still happening, the pattern is changing, and symptoms such as hot flashes or night sweats have started. The next step is usually symptom review, bleeding review, contraception planning, and treatment choice if symptoms are bothersome.
"Menopause" is the better fit only after the 12-month no-period milestone, unless surgery, medication, or hormonal contraception makes the clock hard to read. The next step often shifts toward persistent symptoms, genitourinary symptoms, bone health, cardiometabolic risk, and whether hormone therapy or nonhormonal therapy is appropriate.
"Possible early menopause or primary ovarian insufficiency" is the label that should not be casually folded into normal perimenopause. Symptoms before 45, and especially before 40, can change fertility, bone, cardiovascular, and long-term hormone-replacement discussions. American College of Obstetricians and Gynecologists treats primary ovarian insufficiency as a distinct diagnosis with different stakes than ordinary midlife transition timing. [4]
The label matters because it changes the safest question. The useful question is not "Which hormone number confirms this?" It is "Which stage best fits my age, period pattern, symptoms, risks, and next decision?"
It also changes treatment timing. The 2022 hormone-therapy position statement says hormone therapy remains the most effective treatment for vasomotor symptoms, but risks differ by type, dose, duration, route, timing, and whether a progestogen is used. It describes a more favorable benefit-risk ratio for many symptomatic women younger than 60 or within 10 years of menopause onset who have no contraindications. [5]
Symptoms do not obey the stage boundary perfectly. In Study of Women's Health Across the Nation, frequent vasomotor symptoms lasted a median 7.4 years overall and persisted a median 4.5 years after the final menstrual period among women with an observable final period. That means "I am postmenopausal" does not automatically mean hot flashes or night sweats should be ignored. [6]
Evidence limits: the stage label is a tool, not the diagnosis
The evidence is limited when perimenopause versus menopause is decided by one lab, one symptom, or one month without bleeding. American College of Obstetricians and Gynecologists guidance and the STRAW+10 framework put age and bleeding pattern at the center, while Study of Women's Health Across the Nation shows symptoms can cross the final-period boundary. [1] [2] [6]
That is why the label should answer a practical question: bleeding safety, contraception, symptom treatment, genitourinary syndrome of menopause care, bone or metabolic risk, and whether early menopause or premature ovarian insufficiency needs a different pathway.
Red flags that make "just perimenopause" the wrong frame
Some patterns need evaluation even when perimenopause is likely:
| Pattern | Why it changes the assessment |
|---|---|
| Bleeding after sex or bleeding between periods | American College of Obstetricians and Gynecologists lists these as abnormal bleeding patterns to discuss with a gynecologist. [3] |
| Very heavy bleeding, bleeding that lasts more days than usual, or anemia symptoms | Perimenopause can change bleeding, but heavy or prolonged bleeding still needs evaluation. [3] |
| Any bleeding after 12 months without a period | Postmenopausal bleeding should not be treated as routine perimenopause. |
| Symptoms or cycle changes before age 40 | This raises the possibility of premature ovarian insufficiency, not ordinary midlife transition. [4] |
| Pregnancy possibility, pelvic pain, fever, or sudden severe symptoms | The stage label should wait until urgent or alternative causes are considered. |
| New symptoms while using hormones, high-dose progestogen, or contraception that hides bleeding | Medication can obscure staging and can change what testing means. |
American College of Obstetricians and Gynecologists separates perimenopausal bleeding from bleeding after menopause and encourages evaluation for concerning bleeding patterns rather than assuming all midlife bleeding is ordinary transition change. [3]
What to ask a clinician
Ask:
- Does my age and bleeding pattern fit perimenopause, menopause, or something else?
- Am I on contraception, an intrauterine device, or another medication that hides the pattern?
- Does any bleeding pattern need evaluation before hormone treatment?
- Do I still need contraception?
- If I am under 45, should follicle-stimulating hormone or another evaluation be used differently?
- Which symptoms can be treated now, and which need a separate workup?
- If hot flashes or night sweats are the main problem, do I fit hormone therapy, a nonhormonal option, or a sleep/night-sweat workup?
These questions are more useful than asking for one number to settle the whole transition.
Bottom line
Perimenopause is the transition. Menopause is the 12-month no-period milestone.
After 45, the best first screen is usually period pattern plus symptoms, not a one-time follicle-stimulating hormone or estrogen test. Testing matters more when symptoms start before 45, when the bleeding pattern is abnormal, or when another condition could be causing the symptoms.
Related reading: what perimenopause is, how long perimenopause lasts, perimenopause treatment options, and perimenopause bleeding changes.
References
[1] Harlow SD, Gass M, Hall JE, et al. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. Menopause. 2012;19(4):387-95. doi:10.1097/gme.0b013e31824d8f40 https://pubmed.ncbi.nlm.nih.gov/22343510/
[2] ACOG. Do I need to have testing of my hormone levels during perimenopause?. https://www.acog.org/womens-health/experts-and-stories/ask-acog/do-i-need-to-have-testing-of-my-hormone-levels-during-perimenopause
[3] ACOG. Perimenopausal Bleeding and Bleeding After Menopause. https://www.acog.org/womens-health/faqs/perimenopausal-bleeding-and-bleeding-after-menopause
[4] Committee Opinion No. 698: Hormone Therapy in Primary Ovarian Insufficiency. Obstet Gynecol. 2017;129(5):e134-e141. doi:10.1097/aog.0000000000002044 https://pubmed.ncbi.nlm.nih.gov/28426619/
[5] “The 2022 Hormone Therapy Position Statement of The North American Menopause Society” Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. doi:10.1097/gme.0000000000002028 https://pubmed.ncbi.nlm.nih.gov/35797481/
[6] Avis NE, Crawford SL, Greendale G, et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med. 2015;175(4):531-9. doi:10.1001/jamainternmed.2014.8063 https://pubmed.ncbi.nlm.nih.gov/25686030/